Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11527 posts found.

Cancer and MS drugs approved in Scotland

December 9, 2015 Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia

The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …
News

Five benefits and challenges of the Pfizer/Allergan mega-merger

December 7, 2015 Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Pfizer, acquisitions, mergers, takeovers

Pfizer was extremely keen to get the $160 billion deal done, but what is it getting out of the acquisition, …
Feature

Late-stage failure for Merck and Threshold cancer drug

December 7, 2015 Research and Development, Sales and Marketing Merck, Pancreatic cancer, Threshold Pharmaceuticals, evofosfamide, late-stage failure, phase III, sarcoma

Merck and its development partner Threshold Pharmaceuticals say they will not pursue regulatory approval for evofosfamide in advanced soft tissue …
News

Mylan receives court summons from US Department of Justice

December 7, 2015 Sales and Marketing Drug pricing, Justice department, Mylan, US Department of Justice, generics, investigation, subpoena

The US Department of Justice has contacted Mylan to make enquiries about the company’s pricing structure for antibiotic, doxycycline. Mylan …
News

Takeda reveals five-year Adcetris survival data

December 6, 2015 Research and Development, Sales and Marketing Hodgkin lymphoma, Takeda, oncology

Takeda UK has announced post-treatment follow up data from the pivotal Phase II study of Adcetris revealing a five-year survival …
News

Amgen’s Kyprolis doubles Velcade benefit in head-to-head study

December 5, 2015 Research and Development, Sales and Marketing Amgen, Cancer, Kyprolis, Takeda, Velcade, multiple myeloma

Amgen has announced that its multiple myeloma therapy Kyprolis displayed superiority to Takeda’s Velcade in the Phase III ENDEAVOR study …
News

ALG makes senior hires to increase global growth

December 4, 2015 Manufacturing and Production, Sales and Marketing

Medical products company ALG has hired Matt Guixe as chief operating officer and Jackie Fisher as chief financial officer. Guixe …
Appointment

Pfizer to close UK R&D site in surprise move

December 4, 2015 Research and Development, Sales and Marketing Pfizer

Two weeks after its $160 billion buyout of botox-maker Allergan, Pfizer has announced that it is to close a UK …
News

OBN appoints Dr John Harris as chief executive

December 4, 2015 Medical Communications, Sales and Marketing OBN

OBN, the membership organisation supporting the UK’s emerging life sciences companies, has appointed Dr John Harris as its new chief executive, replacing …
Appointment

Teva strips $1 billion worth of assets to clear Allergan deal

December 4, 2015 Medical Communications, Sales and Marketing Allergan, Teva, acquisitions, divestments, mergers

Teva Pharmaceuticals is thought to be in the process of stripping nearly $1 billion worth of assets to address antitrust …
News

NICE backtracks on Novartis Farydak decision

December 4, 2015 Medical Communications, Sales and Marketing Farydak, NICE, Novartis, panobinostat

NICE has reversed its earlier decision to reject the Novartis drug Farydak as an NHS treatment for people with multiple …
News

Cancer drugs prices vary up to 388% between high-income countries

December 4, 2015 Medical Communications, Sales and Marketing Cancer, Drug pricing, Eli Lilly, Genzyme, Lancet, Novartis, oncology

The price of new cancer drugs varies widely between high-income countries in Europe, Australia, and New Zealand, new research published …
News

Novo Nordisk buys Xoma diabetes program and scores trial successes

December 2, 2015 Research and Development, Sales and Marketing Novo Nordisk, Ryzodeg, SGLT2 inhibitors, Victoza, Xoma, diabetes

Novo Nordisk has announced its purchase of a type 2 diabetes diabetes program in a deal with biotech firm Xoma …
News

Horizon receives European go-ahead for Ravicti

December 2, 2015 Research and Development, Sales and Marketing Horizon Pharma, Ravicti, horizon, orphan drug, rare disease, urea cycle disorders

The European Commission has approved Ravicti for rare urea cycle disorders.  Ravicti, (glycerol phenylbutyrate), is an oral liquid developed by Horizon …
News

Pfizer lung cancer treatment gets expanded EU approval

December 1, 2015 Research and Development, Sales and Marketing NSCLC, Pfizer, Xalkori, crizotinib, lung cancer, non-small cell lung cancer

Pfizer UK has received European Commission approval for a label update to expand use of Xalkori (crizotinib) to first-line treatment …
News
The Gateway to Local Adoption Series

Latest content

Scots neonatal innovations target hearing loss and earlier care

August 28, 2026

FDA grants De Novo authorisation to light-filtering device for migraine

August 28, 2026

Southgate opens Innovation Lab for logistics and fulfilment development

August 27, 2026

Bioptimus partners with Cancer Research Horizons to expand AI cancer data set

August 27, 2026

Agentis Health Group acquires Clinical Pharmacist Solutions

August 26, 2026